Nipah Open Library

Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials

Revision as of 01:57, 7 February 2026 by Nhmkerala (talk | contribs) (Created paper page - 2026-02-07T07:27:23.018232)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Authors: Valerie Rodrigue, Nicole E. Basta, Katie Gravagna

Year: 2024

DOI: 10.1111/tmi.13979

Summary

This paper reviews clinical trials for vaccine and monoclonal antibody candidates designed to prevent Nipah and Hendra diseases in humans.

Key Findings

  • Three vaccine candidates (Hendra Virus Soluble Glycoprotein Vaccine [HeV-sG-V], PHV02, and mRNA-1215) and one mAb (m102.4) have registered human clinical trials.
  • All trials are phase 1, dose-ranging trials taking place in the United States of America or Australia and enrolling healthy adults.

Methodology

  • Study Type: Scoping Review
  • Geographic Focus: ['United States of America', 'Australia']
  • Time Period: Up to June 2023

Topics

Epidemiology, Clinical, Virology

Relevance

The paper provides an overview of the clinical trials for vaccine and monoclonal antibody candidates that could potentially prevent Nipah and Hendra diseases, contributing to the ongoing research and development efforts.

Source

View the entire paper: File:Tropical Med Int Health - 2024 - Rodrigue - Current progress towards prevention of Nipah and Hendra disease in humans A.pdf

Retrieved from "https://nipahlib.phenomi.co/index.php?title=Current_progress_towards_prevention_of_Nipah_and_Hendra_disease_in_humans:_A_scoping_review_of_vaccine_and_monoclonal_antibody_candidates_being_evaluated_in_clinical_trials&oldid=200"